1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Phase III Lasmiditan Data Strengthens Lilly's Dual Migraine Strategy

 
• By Mandy Jackson

Lilly will submit lasmiditan for FDA approval after a second positive Phase III study, giving the company a product to stop migraine when its galcanezumab isn't able to prevent the headaches.

Human brain illustrated with millions of small nerves - Conceptual 3d render

Eli Lilly & Co. will seek US FDA approval for lasmiditan in the acute treatment of migraine headaches in the second half of 2018 – about a year after submission of galcanezumab for the prevention of episodic and chronic migraine – based on the oral drug's success in a second Phase III clinical trial.

The company bought CoLucid Pharmaceuticals Inc. for $960m earlier this year to reclaim the Lilly-discovered lasmiditan for its growing pain portfolio, which includes the CGRP inhibitor galcanezumab. (Also see "Lilly Pays Nearly $1bn To Regain Migraine Candidate It Once Sold For $1m" - Scrip, 19 January, 2017

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.